| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787746 | Journal of Thoracic Oncology | 2018 | 28 Pages |
Abstract
RANKL blocking agents impair the growth of primary lung tumors in several mouse models of lung adenocarcinoma and suggest that patients with KRAS-mutant lung tumors will benefit from such treatments.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Julien PhD, Caroline MS, Nadine PhD, Solange MD, PhD, Etienne PhD,